

References

I-130

1. Yuan X, Gavrilaki E, Brodsky R, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. *Haematologica*. 2017;102:466-475.
2. Sasapu A, Cottler-Fox M, Motwani P. Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab. Baylor University Medical Center Proceedings. 2017;30:182-183.
3. Tran D, Boucher A, Collette S, et al. Eculizumab for the treatment of severe antibody-mediated rejection: A case report and review of the literature. *Case Reports in Transplantation*. 2016;14.
4. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, andomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol*. 2017;976–86.
5. Micromedex DrugDex Compendium®. 2024. Eculizumab.
6. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Eculizumab.
7. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. *Blood*. 2011;6786-6793.
8. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
9. MCGTM Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
10. Soliris® (Eculizumab) [package insert]. Alexion Pharmaceuticals, Inc. Boston, MA. 2007. Revised 11/2020.
11. Ultomiris™ (ravulizumab-cwvz) [package insert]. Alexion Pharmaceuticals, Inc. Boston, MA. 2018. Revised 03/2024.
12. Hayes, Inc. Hayes Prognosis Overview. Ultomiris (Ravulizumab-cwvz) for Paroxysmal Nocturnal Hemoglobinuria. Landsdale, PA: Hayes, Inc.; January 2019.
13. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. *N Engl J Med*. 2019;381(7):614-625.
14. Kulasekararaj A, Hill A, Rottinghaus S, et al. Ravulizumab (ALXN1210) vs eculizumab in C5inhibitor-experienced adult patients with PNH: the 302 study. *Blood*. 2019;133(6): 540– 549.
15. Wook Lee J, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood*. 2019; 133(6): 530– 539.
16. Hayes, Inc. Hayes Precision Therapy Assessment. Eculizumab (Soliris) for treatment of Refractory Generalized Myasthenia Gravis. Lansdale, PA: Hayes, Inc.; February 2021
17. Hayes, Inc. Emerging Technology Report. Ultomiris (Ravulizumab-cwvz) for Paroxysmal Nocturnal Hemoglobinuria. Lansdale, PA: Hayes, Inc.; July 2019.

18. Roth A, Rottinghaus S, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. *Blood Adv*. 2018;2(17):2176-2185.
19. Empaveli™ (pegcetacoplan), injection, for subcutaneous use [package insert]. Apellis Pharmaceuticals, Inc. Waltham, MA. Revised 05/2021.
20. Eculizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 27, 2019.
21. Ravulizumab-cwvz In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 10, 2024.
22. Pegcetacoplan In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 28, 2021.
23. Micromedex DrugDex Compendium®. 2024. Pegcetacoplan.
24. Micromedex DrugDex Compendium®. -2024. Ravulizumab-cwvz.
25. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med*. 2021;384(11):1028-1037.
26. Bhak RH, Mody-Patel N, Baver SB, et al. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. *Curr Med Res Opin*. 2021;37(11):1913-1923.
27. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Ravulizumab-cwvz.
28. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Pegcetacoplan.
29. Howard James F, Vu Tuan, Mantegazza Renato et al. Long-term efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Results from the phase 3 CHAMPION MG open-label extension. 2022;98(18)853.
30. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. *Ann Neurol*. 2023;93(6):1053-1068.
31. Piasky® (crovalimab-akkz) injection, for intravenous or subcutaneous use. [package insert]. Genentech Inc. South San Francisco, CA. Revised 06/2024.
32. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Crovalimab-akkz.
33. Micromedex DrugDex Compendium®. 2024. Crovalimab-akkz.
34. Röth A, He G, Brodsky A, et al. S181: the phase III, randomized commodore 2 trial: results from a multicenter study of crovalimab vs eculizumab in paroxysmal nocturnal hemoglobinuria (pnh) patients naive to complement inhibitors. *Hemasphere*. 2023;7(3):e72750f1.
35. Liu H, Xia L, Weng J, et al: Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naïve patients with PNH (COMMODORE 3): a multicenter, phase 3, single-arm study. *Am J Hematol*. 2023; 98(9):1407-1414.